ইউরোপীয় ইউনিয়ন - চেক - EMA (European Medicines Agency)

pierre fabre medicament - propranolol-hydrochloridu - hemangiom - beta blokátory - hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy: , life- or function-threatening haemangioma,, ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, haemangioma with a risk of permanent scars or disfigurement. , it is to be initiated in infants aged 5 weeks to 5 months.

ইউরোপীয় ইউনিয়ন - চেক - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - karcinom, plicní jiná než malobuněčná - jiná cytostatika, inhibitory proteinkinázy - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

ইউরোপীয় ইউনিয়ন - চেক - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - treosulfan - transplantace hematopoetických kmenových buněk - antineoplastická činidla - treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (allohsct) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.

ইউরোপীয় ইউনিয়ন - চেক - EMA (European Medicines Agency)

ptc therapeutics international limited - eladocagene exuparvovec - metabolismus aminokyselin, vrozené chyby - enzymes, other alimentary tract and metabolism products - upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic l amino acid decarboxylase (aadc) deficiency with a severe phenotype (see section 5.

চেক প্রজাতন্ত্র - চেক - SUKL (Státní ústav pro kontrolu léčiv)

almirall hermal gmbh, reinbek array - 1354 ČiŠtĚnÝ sÓjovÝ olej - přísada do koupele - 0,8475g/ml - mĚkkÝ parafin a tukovÉ produkty

চেক প্রজাতন্ত্র - চেক - SUKL (Státní ústav pro kontrolu léčiv)

belupo, s.r.o., bratislava array - 2065 betamethason-dipropionÁt - krém - 0,5mg/g - betamethason

চেক প্রজাতন্ত্র - চেক - SUKL (Státní ústav pro kontrolu léčiv)

belupo, s.r.o., bratislava array - 2065 betamethason-dipropionÁt - mast - 0,5mg/g - betamethason

চেক প্রজাতন্ত্র - চেক - SUKL (Státní ústav pro kontrolu léčiv)

apta medica internacional d.o.o., ljubljana array - 16593 sodnÁ sŮl ertapenemu - prášek pro koncentrát pro infuzní roztok - 1g - ertapenem

চেক প্রজাতন্ত্র - চেক - SUKL (Státní ústav pro kontrolu léčiv)

aurovitas, spol. s r.o., praha array - 16593 sodnÁ sŮl ertapenemu - prášek pro koncentrát pro infuzní roztok - 1g - ertapenem

চেক প্রজাতন্ত্র - চেক - SUKL (Státní ústav pro kontrolu léčiv)

fresenius kabi s.r.o., praha array - 16593 sodnÁ sŮl ertapenemu - prášek pro koncentrát pro infuzní roztok - 1g - ertapenem